Loading...

Shanghai Junshi Biosciences Co., Ltd.

1877.HK•HKSE
Healthcare
Biotechnology
HK$20.90
HK$-1.80(-7.93%)

Shanghai Junshi Biosciences Co., Ltd. (1877.HK) Stock Overview

Explore Shanghai Junshi Biosciences Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.1/100

Key Financials

Market Cap31.3B
P/E Ratio-14.65
EPS (TTM)$-1.42
ROE-0.20%

AI Price Forecasts

1 Week$23.77
1 Month$22.49
3 Months$5.53
1 Year Target$8.02

1877.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Shanghai Junshi Biosciences Co., Ltd. (1877.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.03, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $8.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -14.65 and a market capitalization of 31.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

73.03RSI (14)
2.04MACD
32.52ADX
Stats data is not available for 1877.HKStats details for 1877.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1877.HKAnalyst Recommendations details for 1877.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

CEO

Cong Li

Employees

2,578

Headquarters

Building 7, Shanghai

Founded

2018

Frequently Asked Questions

;